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ABSTRACT
Background and Objectives: We sought to determine parameters to guide the decision of retreatment in patients with Ka-
wasaki disease (KD) who remained febrile after initial intravenous immunoglobulin (IVIG). Subjects and Methods: A to-
tal of 129 children with KD were studied prospectively. Patients were treated with IVIG 2 to 9 days after the onset of disease. 
Laboratory measures, such as white blood cell (WBC), percentage of neutrophils, C-reactive protein (CRP), and N-terminal 
pro-brain natriuretic peptide (NT-proBNP), were determined before and 48 to 72 hours after IVIG treatment. Patients were 
classified into IVIG-responsive and IVIG-resistant groups, based on the response to IVIG. Results: Of a total of 129 patients, 
107 patients (83%) completely responded to a single IVIG therapy and only 22 patients (17%) required retreatment: 14 had 
persistent fever and 8 had recrudescent fever. There was no significant difference between the groups in age, gender distri-
bution, and duration of fever to IVIG initiation, but coronary artery lesions developed significantly more often in the resis-
tant group than in the responsive group (31.8% vs. 2.8%, p=0.000). Compared with pre-IVIG data, post-IVIG levels of WBC, 
percentage of neutrophils, CRP, and NT-proBNP decreased to within the normal range in the responsive group, whereas they 
remained high in the resistant group. Multivariate logistic regression indicated that neutrophil counts, CRP, and NT-proBNP 
were independent parameters of retreatment. Conclusion: Additional therapy at an early stage of the disease should be ad-
ministered for febrile patients who have high values of CRP, NT-proBNP, and/or neutrophil counts after IVIG therapy. (Ko-
rean Circ J 2011;41:379-384)
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Introduction
Intravenous immunoglobulin (IVIG) infusion is an effec-
tive therapy for acute Kawasaki disease (KD).
1) Administra-
tion within a few days of illness of a single dose of IVIG, in 
combination with high-dose aspirin, ceases fever, rapidly re-
solves clinical signs and symptoms of inflammation, and re-
duces the incidence of coronary artery aneurysms.
1)2) How-
ever, approximately 10% to 20% of KD patients have persist-
ent or recrudescent fever, despite IVIG therapy.
2)3) 
When fever persists or recurs with signs of mucocutaneous 
inflammation after initial IVIG therapy, retreatment can be 
indicated. However, when the patients have fever with few cli-
nical signs of ongoing inflammation, these patients pose a th-
erapeutic dilemma. The KD patients who fail to respond to 
initial IVIG treatment should be reassessed to exclude the pos-
sibility of a bacterial infection. Although current diagnostic 
criteria for KD require exclusion of infectious diseases before 
making a definite diagnosis, there are actually several reports 
of patients with typical features of KD, including coronary ar-
tery aneurysm, who also have had a documented infection.
4)5) 
In addition, we have sometimes experienced KD patients 
who became afebrile with IVIG treatment, but shortly febrile 
again due to newly developed viral infection, pharyngoton-
sillitis, gastroenteritis, or urinary tract infection during hos-
pitalization. In such cases, the values of acute phase reactants 
were usually within the normal range and fever subsided with-380   Parameters of Retreatment in Kawasaki Disease
out the use of IVIG. In patients who remain febrile despite 
IVIG therapy, our institutional protocol requires that we al-
ways deliberate on the values of acute phase reactants, when 
a need for additional therapy is recognized. If the patients be-
come afebrile after treatment, no laboratory test is perform-
ed. Most physicians clinically judge post-IVIG fever to be at-
tributable to active KD, rather than to other causes,
2)6) and tend 
to retreat this group of patients in the absence of the systemic 
evaluation required to guide the decision of treatment. We be-
lieve that there is a need for objective laboratory measures 
that identify KD patients who remain febrile after IVIG treat-
ment and therefore need additional therapy. 
Our goal was to determine from routine laboratory meas-
ures the parameters that may serve to guide retreatment in 
KD patients who remained febrile after initial IVIG therapy. 
Subjects and Methods
During the study period between November 2008 and Sep-
tember 2010, a total of 129 children who met the diagnostic 
criteria for KD
7) were prospectively enrolled. Subjects com-
prised 72 boys (55.8%) and 57 girls, aged 2 months to 11 
years. All patients were treated with IVIG 2 g/kg for 2 to 9 
days after the onset of disease, and were also given aspirin 
80 to 100 mg/kg/day until defervescence, and then 5 mg/kg/
day as a single daily dose. When the patients failed to defer-
vesce after the first IVIG therapy, they were retreated with a 
second dose of IVIG (n=14). When they remained still febrile 
despite a second dose of IVIG therapy, then pulse methyl-
prednisolone (30 mg/kg/day for 3 days) was administered 
(n=8). 
We measured white blood cell (WBC), percentage of neu-
trophils in WBCs (% neutrophils), hematocrit, platelet counts, 
serum sodium, total bilirubin, aspartate aminotransferase, 
alanine aminotransferase (ALT), protein, albumin, C-reac-
tive protein (CRP), and N-terminal pro-brain natriuretic pep-
tide (NT-proBNP), before and 48 to 72 hours after IVIG tr-
eatment. For patients who failed to respond to the second 
dose of IVIG, laboratory measures were repeated before pulse 
steroid therapy. Coronary arteries were assessed by echocar-
diography performed at the time of diagnosis and at disch-
arge, and repeated at weeks 2, 4, and 8 after treatment, and 
then as needed thereafter. Coronary artery lesions (CALs) 
were diagnosed according to the criteria of the Japanese Mi-
nistry of Health and Welfare.
8) Patients who presented with 
CAL before the initial treatment were excluded from the study. 
Subjects were divided into 2 groups according to respon-
siveness to IVIG treatment: IVIG-responsive patients (n= 
107) and IVIG-resistant patients (n=22). Laboratory mea-
sures before and after IVIG therapy were compared in each 
group. We selected the variables that showed a different ch-
ange after IVIG therapy between the groups. Pre- and post-
IVIG concentrations of each variable between the groups 
were compared. The value of the fractional change (FC) of 
each variable between the groups was also compared, as de-
scribed previously.
9) FC was defined as follows:
 
FC=(Y-X)/X 
In which X represents data before IVIG treatment and Y re-
presents data at 48 to 72 hours after IVIG treatment.
This study was approved by the Institutional Review Bo-
ard of Ewha Womans University Mokdong Hospital (#ECT 
230-2-28) and written informed consents were obtained 
from the parents of each patient.
Definitions
Duration of fever was defined as the time from the onset 
of disease to the start of initial IVIG infusion. Persistent fe-
ver was defined as temperature ≥38°C that persisted beyond 
48 hours after completion of the IVIG infusion. Recrudes-
cent fever was defined as temperature <37.5°C for more than 
24 hours after IVIG infusion, followed by temperature ≥38°C. 
IVIG-responsive patients were defined as patients who had 
defervescence within 48 hours after initial IVIG infusion. 
IVIG-resistant patients were defined as those who required 
additional rescue therapy, owing to either persistent or recru-
descent fever at least 48 hours after the end of initial IVIG 
infusion.
Data analyses
All data were analyzed with the Statistical Package for the 
Social Sciences for Windows software (SPSS) version 12.0 
(SPSS Inc, Chicago, IL, USA). Data are presented as either 
mean±SD for continuous variables or as the number (percen-
tage) of patients for categorical variables. Intra-group vari-
ables were compared using the paired t-test, and inter-group 
variables and FCs using the Student t-test. Proportions were 
compared using either the χ2 test or the Fisher’s exact test. To 
determine the cutoff value of each parameter found to be 
significant by FC, receiver operating characteristic (ROC) 
curves were used. Multivariate logistic regression analysis 
was used to determine independent parameters of retreat-
ment and results were expressed as an odds ratio with a 95% 
confidence interval (CI). A 95% CI that did not include 1.0 
was interpreted to indicate statistical significance. A level of 
p<0.05 was considered as statistically significant.
 
Results
Clinical characteristics of intravenous 
immunoglobulin-resistant patients
Of a total of 129 patients, 107 patients (83%) completely 
responded to a single IVIG therapy and 22 patients (17%) Hyun Kwon Kim, et al.   381
required retreatment: 14 had persistent fever and 8 had re-
crudescent fever. Of the 14 patients with persistent fever, 7 
patients achieved defervescence after the second dose of 
IVIG. However, the remaining 7 failed to respond to the 
second IVIG therapy and received pulse methylprednisolone 
therapy. In contrast, 7 of the 8 patients with recrudescent fe-
ver achieved defervescence after the second course of IVIG. 
However, according to fever pattern, no significant difference 
in responsiveness to a second dose of IVIG was found (p= 
0.086). 
IVIG-resistant patients did not differ from the IVIG-re-
sponsive patients with respect to age, gender distribution, and 
duration of fever measured until IVIG initiation. However, 
CALs developed significantly more often in the IVIG-resis-
tant patients than in IVIG-responsive patients (Table 1).
Changes in laboratory measures after intravenous 
immunoglobulin therapy in responsive patients 
Compared with pre-IVIG data, post-IVIG levels of WBC, 
% neutrophils, total bilirubin, CRP, and NT-proBNP decre-
ased to within the normal range and protein concentration 
increased (Table 2). 
There were 8 patients who became afebrile but had high 
values of CRP (4.01 to 8.69 mg/dL) and NT-proBNP (338 to 
3,308 pg/mL) after IVIG treatment. We repeated the labora-
tory tests and confirmed their normalization. 
Changes in laboratory measures after intravenous 
immunoglobulin therapy in resistant patients 
There was no difference between pre- and post-IVIG data 
in WBC, % neutrophils, protein, albumin, CRP, and NT-pro-
BNP. The values of WBC, % neutrophils, CRP, and NT-pro-
BNP remained high after IVIG treatment (Table 3). Parado-
xically, WBC counts were elevated in 35% of IVIG-resistant 
children (vs. 9.4% in responsive patients, p=0.001), % neutro-
phils in 15% (vs. 4.7% in responsive patients, p=0.15), CRP 
in 23.8% (vs. 0.9% in responsive patients, p=0.000), and NT-
proBNP in 47.4% (vs. 14% in responsive patients, p=0.002) 
after IVIG therapy, as compared with pre-IVIG data. 
In 8 patients who remained febrile after a second dose of 
IVIG and required pulse steroid therapy, the lab measures 
before the second dose of IVIG did not significantly differ 
from those before steroid therapy: WBC, 14,400±6,100 vs. 
14,800±3,600, p=0.885; % neutrophils, 65±9 vs. 62±14, p= 
0.684; CRP, 8.8±5.1 vs. 6.8±3.4, p=0.438; and NT-proBNP, 
4,800±5,400 vs. 3,100±3,800, p=0.518.
There were 2 patients who remained febrile despite the se-
cond dose of IVIG therapy but had normal laboratory mea-
sures, including CRP (1.08 mg/dL and 0.71 mg/dL, respecti-
vely). We just observed them, without using the steroid, and 
they achieved defervescence 24 to 33 hours later.
 
Fractional change of laboratory parameters 
We excluded 5 variables that showed a similar change after 
IVIG treatment between IVIG-responsive and IVIG-resis-
tant patients, and selected the remaining 7 variables that sh-
Table 1. Comparison of basic characteristics between IVIG-res-
ponsive and IVIG-resistant patients
Responsive
(n=107)
Resistant
(n=22)
     p
Age (month) 29.0±20.8 35.9±28.6 0.212
Gender (male/female) 57/50 15/7 0.147
Duration of fever to IVIG (d) 4.3±1.6 3.8±1.8 0.921
CAL, n (%) 3 (2.8) 7 (31.8) 0.000
IVIG: intravenous immunoglobulin, CAL: coronary artery lesion
Table 2. Comparison between pre- and post-IVIG laboratory me-
asures in IVIG-responsive patients 
Pre-IVIG Post-IVIG   p
WBC (/mm
3)  13,800±4,500 8,200±2,800 0.002 
% neutrophils 061.6±15.6 33.7±16.3 0.000 
Hematocrit (%) 33.3±2.6 32.4±3.00 0.000 
Platelet (×10
3/mm
3)  338±90 438±132 0.000 
Sodium (mEq/L)  136.4±2.50 135.8±10.70 0.874 
Total bilirubin (mg/dL)  00.6±0.4 0.2±0.1 0.000 
AST (IU/L)  0135±290 135±368 0.491 
ALT (IU/L)  0117±208 116±325 0.845 
Protein (g/dL)  06.5±0.5 7.8±0.8 0.000 
Albumin (g/dL)  03.8±0.3 3.3±0.3 0.001 
CRP (mg/dL)  08.6±6.2 1.4±1.3 0.000 
NT-proBNP (pg/mL)  01,132±1,651 274±315 0.000 
IVIG: intravenous immunoglobulin, WBC: white blood cell, AST: as-
partate aminotransferase, ALT: alanine aminotransferase, CRP: C-re-
active protein, NT-proBNP: N-terminal pro-brain natriuretic peptide
Table 3. Comparison between pre- and post-IVIG laboratory meas-
ures in IVIG-resistant patients 
Pre-IVIG Post-IVIG  p
WBC (/mm
3)  14,500±6,500 12,900±4,900 0.657 
% neutrophils 074.3±12.2 059.4±12.0 0.329 
Hematocrit (%) 33.3±3.2 30.3±2.9 0.002 
Platelet (×10
3/mm
3)  0308±109 0345±119 0.001
Sodium (mEq/L)  134.0±2.40 136.0±2.50 0.885 
Total bilirubin (mg/dL)  01.4±1.6 00.4±0.4 0.000 
AST (IU/L)  0203±300 053±53 0.775 
ALT (IU/L)  0229±355 0101±114 0.000 
Protein (g/dL)  06.1±0.7 06.8±0.7 0.636 
Albumin (g/dL)  03.6±0.6 02.8±0.5 0.327 
CRP (mg/dL)  09.9±4.1 06.8±4.6 0.348 
NT-proBNP (pg/mL)  02,960±4,160 02,740±3,970 0.701 
IVIG: intravenous immunoglobulin, WBC: white blood cell, AST: as-
partate aminotransferase, ALT: alanine aminotransferase, CRP: C-re-
active protein, NT-proBNP: N-terminal pro-brain natriuretic peptide382   Parameters of Retreatment in Kawasaki Disease
owed a different post-IVIG change between the groups: WBC, 
% neutrophils, ALT, protein, albumin, CRP, and NT-proBNP. 
Of these variables, ALT was also excluded from the further an-
alysis because its post-IVIG level in the resistant group decreas-
ed toward the normal range. 
Pre- and post-IVIG concentrations of the 6 variables were 
compared between the groups (Table 4). There was no differ-
ence between the groups in pre-IVIG levels of WBC, CRP, and 
NT-proBNP. However, the value of % neutrophils was higher 
and the concentrations of protein and albumin were lower 
in the IVIG-resistant patients. With regard to post-IVIG data, 
all 6 variables showed a significant difference between the 
groups. To verify the possibility that post-IVIG differences 
between the groups in % neutrophils, protein, and albumin 
may be derived from their pre-IVIG differences, FCs of the 6 
variables were determined (Table 5). As expected from Table 
4, WBC, CRP, and NT-proBNP showed a significant FC dif-
ference between the groups. Except for protein and albumin, 
there was a significant inter-group difference in FC of % neu-
trophils, indicating that its post-IVIG difference seen in Table 
4 was not derived from the pre-IVIG difference. Therefore, th-
ese 4 variables may represent suitable parameters to guide the 
decision of retreatment in IVIG-resistant KD. 
Cutoff values of parameters 
The cutoff value of parameters was determined by ROC cur-
ves: a WBC cutoff value of 10,850/mm
3 provided a sensitivity 
of 80% and a specificity of 84%, with an area under the curve 
(AUC) of 0.838±0.057 (95% CI, 0.73-0.95, p=0.000); a % neu-
trophils cutoff value of 53.4% provided a 75% sensitivity and 
a 87.7% specificity {AUC=0.896±0.031 (95% CI, 0.84-0.96, 
p=0.000)}; a CRP cutoff value of 3.68 mg/dL yielded 76.2% 
sensitivity and 92.5% specificity {AUC=0.905±0.041 (95% 
CI, 0.83-0.99, p=0.000)}; and a NT-proBNP cutoff value of 
479 pg/mL yielded 78.9% sensitivity and 86.0% specificity 
{AUC=0.883±0.05 (95% CI, 0.79-0.98, p=0.000)}. 
 
Independent parameters of retreatment
By multivariate logistic regression analysis, % neutrophils, 
CRP, and NT-proBNP were identified as independent para-
meters of retreatment (Table 6). Patients with post-IVIG CRP 
≥3.68 mg/dL, NT-proBNP ≥479 pg/mL, and/or % neutro-
phils ≥53.4% were subjected to retreatment, with a sensitivi-
ty of 80% and a specificity of 96.3%. 
Discussion
Although IVIG plus aspirin therapy are effective for the treat-
ment of acute KD,
1) approximately 10% to 20% of patients ex-
perience either persistent or recrudescent fever, despite ini-
tial IVIG treatment.
2)3) These patients are at increased risk of 
developing coronary artery aneurysm.
2)10)11) Therefore, it is 
important to determine the effectiveness of IVIG soon after 
therapy, especially in resistant cases, to recognize a need for 
additional therapy, such as a second dose of IVIG, steroids, or 
infliximab.
12)13) However, no evaluation system currently ex-
ists to determine the effectiveness of IVIG therapy. Both fever 
resulting from cytokine release and increased CRP levels me-
diated by interleukin-6 are clinically useful measures of sys-
temic inflammation in KD. Post-IVIG fever, however, may ar-
ise from other causes (e.g., intercurrent infection), as well as 
from KD itself during hospitalization. Thus other adjuvant in-
flammatory markers may be required to more precisely assess 
the ongoing inflammation arising from KD and to support 
the decision for retreatment in patients who remain febrile af-
ter IVIG therapy. We investigated routine laboratory meas-
ures and propose herein CRP, NT-proBNP, and % neutro-
phils as independent parameters to guide the decision of retreat-
ment in KD patients who are still febrile after initial IVIG th-
Table 4. Comparison of pre- and post-IVIG laboratory measures between IVIG-responsive and IVIG-resistant patients
 Pre-IVIG
p
 Post-IVIG
p
Responsive Resistant Responsive Resistant
WBC 13,800±4,500 14,500±6,500 0.688 8,200±2,800 12,900±4,900 0.000
% neutrophils 061.6±15.6 074.3±12.2 0.000 33.7±16.3 059.4±12.0 0.000
Protein 06.5±0.5 06.1±0.7 0.025 7.8±0.8 06.8±0.7 0.003
Albumin 03.8±0.3 03.6±0.6 0.004 3.3±0.3 02.8±0.5 0.046
CRP 08.6±6.2 09.9±4.1 0.337 1.4±1.3 06.8±4.6 0.000
NT-proBNP 01,132±1,651 02,960±4,160 0.096 274±315 02,740±3,970 0.013
IVIG: intravenous immunoglobulin, WBC: white blood cell, CRP: C-reactive protein, NT-proBNP: N-terminal pro-brain natriuretic peptide
Table 5. Fractional changes of laboratory parameters 
FC*
p
Responsive Resistant
WBC  -0.36±0.29  -0.01±0.60  0.011
% neutrophils  -0.45±0.25  -0.18±0.22  0.000
Protein  -0.16±0.21  -0.13±0.17  0.777
Albumin -0.14±0.08  -0.20±0.19  0.362
CRP -0.76±0.75  -0.27±0.60  0.005
NT-proBNP -0.51±0.61  -0.99±3.10  0.045
*FC=(Data at 48 to 72 hours after IVIG)-(Data before IVIG)/Data 
before IVIG. WBC: white blood cell, CRP: C-reactive protein, NT-
proBNP: N-terminal pro-brain natriuretic peptide, FC: fractional 
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erapy.
In this study, IVIG-resistance occurred in 17% of KD pa-
tients. The clinical indications for retreatment were persistent 
fever in 14 patients and recrudescent fever in 8 patients. Of 
these 22 patients retreated with a second dose of IVIG, 14 
patients (63.6%) achieved defervescence with this treatment. 
This finding was similar to results of other studies in which ap-
proximately two thirds of the initial non-responders eventual-
ly responded to a second dose of IVIG.
3)6) In addition, alth-
ough there was no statistical significance, persistent fever was 
likely to cease either by a second dose of IVIG or by steroid th-
erapy, whereas recrudescent fever was more likely to cease by 
a second dose of IVIG only. 
The optimal period to begin IVIG administration remains 
controversial. Some investigators reported that early treat-
ment, i.e., before day 5 of illness, is associated with increased 
need for additional IVIG therapy.
14) Contrarily, others advo-
cated that earlier treatment would be better.
15) In this study, 
we found no difference between the IVIG-responsive and 
IVIG-resistant group in the proportion of patients who were 
treated before day 5 of illness (62.0% vs. 77.3%, p=0.215) and 
also in the mean duration of fever until IVIG initiation. Thus 
neither group was affected by the time of IVIG administration 
in this study. 
The patients who failed to defervesce after IVIG therapy 
were characterized by significantly higher values of post-IV-
IG WBC, % neutrophils, CRP, and NT-proBNP, compared 
with IVIG-responsive patients. Thus, we demonstrated that 
WBC, % neutrophils, CRP, and NT-proBNP may be suitable 
parameters of retreatment after initial IVIG therapy. When 
assessed by multivariate analysis, the neutrophil counts and 
serum concentrations of CRP and NT-proBNP were found 
to be independent parameters of the response to IVIG therapy. 
Both the sensitivity and specificity of these 3 independent pa-
rameters, as defined in this study, may allow clinicians to iden-
tify patients who remain febrile and need additional therapy 
after initial IVIG treatment. We are able to justify retreatment 
more reliably by measuring not only CRP, but also NT-proB-
NP and % neutrophils, rather than CRP alone. 
Our results were similar to the findings of Mori et al.
9) who 
demonstrated that increased WBC, neutrophil counts, and 
CRP after IVIG treatment are markers of treatment efficacy 
and also useful predictors of CALs. The role of neutrophils 
in acute KD has been elucidated. Neutrophil activation can 
occur by stimulation of increased granulocyte colony-stim-
ulating factor and cytokines that are involved in coronary ar-
tery dilation.
16)17) In the acute phase of disease, enhanced neu-
trophil function may contribute to the pathogenesis of coro-
nary vascular endothelial injury through either production of 
elastase or expression of vascular endothelial growth factor.
17)18) 
This was demonstrated in a pathologic study showing early 
infiltration of neutrophils in the CALs of patients who died 
10 days after the onset of disease.
19) Thus, it is natural that neu-
trophil is a marker of systemic inflammation. As a parameter 
in the multivariate analysis, the neutrophil count is interpret-
ed to be more significant than WBC.
We proposed a CRP cutoff value of 3.68 mg/dL as a marker 
of ongoing inflammation after IVIG therapy. This value is si-
milar to 4 mg/dL calculated as the upper limit of post-IVIG 
CRP (mean+2 SDs) in the responsive group, as shown in Table 
4, but is still a little higher than the value of 3 mg/dL, proposed 
by the American Heart Association as a criterion for the evalu-
ation of suspected incomplete KD.
20) 
We reported previously that NT-proBNP increases during 
the acute phase of KD, i.e., before IVIG treatment, and decrea-
ses to within the normal range in the convalescent phase.
21) The 
change in NT-proBNP according to the phase of KD is equi-
valent to that in CRP, suggesting that NT-proBNP may be 
used as a marker of systemic inflammation, as well as myo-
cardial involvement, in acute KD. This finding is consistent 
with that of the other study.
22) Moreover, the fact that, after 
IVIG administration, NT-proBNP was paradoxically elevat-
ed in nearly half of IVIG-resistant patients suggests that NT-
proBNP may be a useful marker of ongoing inflammation 
after IVIG treatment as well. Thus we put an emphasis on the 
clinical significance of NT-proBNP as a marker of retreat-
ment. A NT-proBNP cutoff value of 479 pg/mL, indicated as 
a marker of retreatment in the present study, was higher than 
both 260 pg/mL and 170 pg/mL proposed as a diagnostic test 
of acute KD in our previous study, 
21) and in the other study,
22) 
respectively.
Using the defined parameters, here are our suggested guide-
lines of retreatment for KD patients who receive IVIG treat-
ment: 1) Do necessarily retreat patients who remain febrile 
despite IVIG therapy and have high values of CRP, NT-proB-
NP and/or neutrophil counts; 2) When the patients become 
Table 6. Multivariate logistic analysis for parameters of retreatment
Logistic coefficient (β) SE Odds ratio
95% CI
Lower Upper
WBC (10,850/mm
3) 0.93 0.99 02.54 0.36  17.69
Neutrophils (53.4%) 3.11 1.26 22.32 1.88 264.94
CRP (3.68 mg/dL) 2.16 1.03 08.68 1.14  65.75
NT-proBNP (479 pg/mL) 2.67 1.24 14.43 1.27 163.34
WBC: white blood cell, CRP: C-reactive protein, NT-proBNP: N-terminal pro-brain natriuretic peptide 384   Parameters of Retreatment in Kawasaki Disease
febrile and show normal lab measures (i.e., parameters), do 
not retreat for KD and observe for 1 to 2 days, with anticipa-
tion of defervescence. In these cases, fever is less likely to be 
caused by KD; 3) When the patients become afebrile and show 
abnormal lab values/parameters, do not retreat them and re-
peat laboratory tests; 4) Do not retreat patients who become 
afebrile and have normal parameters.
In conclusion, our study shows that, in KD patients who re-
main febrile despite IVIG treatment, additional therapy can 
be facilitated early by measuring CRP in combination with 
NT-proBNP and/or % neutrophils. Further study in a larger 
sample of patients is warranted to clarify our guidelines of 
retreatment for KD patients. 
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